Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Elastin microfibril interfacer 3 (EMILIN3) is an extracellular matrix glycoprotein in the EMILIN/Multimerin protein family, characterized by an N-terminal cysteine-rich EMI domain. EMILIN3 is the least characterized member of its family and displays a dynamic and tissue-specific expression pattern, mainly localizing in developing gonads, osteogenic mesenchyme, and connective tissues. In skin, it localizes to the tips of oxytalan fibers and specialized basement membranes surrounding hair follicles and sebaceous glands. It serves structural roles in the extracellular matrix, can oligomerize, and modulates signaling by functioning as an extracellular antagonist of transforming growth factor β (TGF-β) ligands. EMILIN3 is reported as a marker of changes in the dermal extracellular matrix and as potentially involved in carcinogenesis and tissue remodeling, although it is not described as a direct therapeutic target and there are no known pharmacological agents directed against it.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Elastin microfibril interfacer 3 (EMILIN3).